Established, emerging and future roles of PET/CT in the management of colorectal cancer

Herbertson, R.A.; Scarsbrook, A.F.; Lee, S.T.; Tebbutt, N.; Scott, A.M.

doi:10.1016/j.crad.2008.08.008

« Previous Next »Clinical Radiology
Volume 64, Issue 3 , Pages 225-237, March 2009

Established, emerging and future roles of PET/CT in the management of colorectal cancer

R.A. Herbertson
- Ludwig Institute for Cancer Research, Melbourne Centre for Clinical Sciences, Austin Health, Heidelberg, Victoria, Australia
- Guarantor and correspondent: R.A. Herbertson, Tumour Targeting Research Fellow, Ludwig Institute for Cancer Research, Melbourne Centre for Clinical Sciences, 1st Floor, Harold Stokes Building, Austin Hospital, 145 Studley Road, Heidelberg, Victoria 3084, Australia. Tel.: +61-394963098.
A.F. Scarsbrook
- Department of Radiology, St James's University Hospital, Leeds, UK
S.T. Lee
- Centre for PET
N. Tebbutt
- Ludwig Institute Oncology Unit, Austin Health, Heidelberg, Victoria, Australia
A.M. Scott
- Ludwig Institute for Cancer Research, Melbourne Centre for Clinical Sciences, Austin Health, Heidelberg, Victoria, Australia
- Centre for PET

Received 11 April 2008; received in revised form 5 August 2008; accepted 7 August 2008.

Positron-emission tomography–computed tomography (PET/CT) is rapidly being integrated into the imaging pathways of several different tumour types, most frequently using the glucose analogue 2- [¹⁸F]-fluoro-2-deoxy-d-glucose (FDG). Integrated FDG-PET/CT combines functional and anatomical imaging to improve sensitivity and specificity of tumour detection. The aim of this article is to review the established, emerging, and future roles of FDG-PET/CT in the management of patients with colorectal cancer (CRC).